FDA Approves Mayne’s Halobetasol Foam For Adolescents
Australian Company Strengthens Its Dermatology Portfolio With US Lexette Nod
Mayne Pharma has announced receiving US FDA approval for its Lexette (halobetasol propionate) 0.05% foam for the treatment of plaque psoriasis for use in adolescents. With Lexette, Mayne now markets more than twenty dermatology products in the US including four branded products.
